Furthermore, the overall response rate (ORR) was 50% in HHLA2-positive patients and 14.3% in negative patients (Figure 5C), suggesting that high HHLA2 expression could be recognized as a sign of better response to immunotherapy in melanoma patients. The gene discussed is HHLA2; the disease is melanoma.